2020
A National Study of Surgically Managed Atypical Pulmonary Carcinoid Tumors
Walters SL, Canavan ME, Salazar MC, Resio BJ, Blasberg JD, Mase V, Boffa DJ. A National Study of Surgically Managed Atypical Pulmonary Carcinoid Tumors. The Annals Of Thoracic Surgery 2020, 112: 921-927. PMID: 33159862, DOI: 10.1016/j.athoracsur.2020.09.029.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoid TumorFemaleHumansLung NeoplasmsMaleMiddle AgedSurvival RateTreatment OutcomeUnited StatesConceptsAtypical pulmonary carcinoid tumorsPulmonary carcinoid tumorsCarcinoid tumorsCarcinoid patientsAtypical carcinoidStage IMultivariable Cox proportional hazards regressionNon-small cell lung cancerCox proportional hazards regressionAtypical carcinoid patientsTypical pulmonary carcinoidNational Cancer DatabasePredictors of survivalOptimal surgical managementAtypical carcinoid tumorCell lung cancerProportional hazards regressionKaplan-Meier survivalLong-term survivalNodal upstagingSurgical resectionMultivariable analysisSurgical managementHazards regressionLarge tumorsInvasive Staging Procedures Do Not Prevent Nodal Metastases From Being Missed in Stage I Lung Cancer
Resio BJ, Canavan M, Mase V, Dhanasopon AP, Blasberg JD, Boffa DJ. Invasive Staging Procedures Do Not Prevent Nodal Metastases From Being Missed in Stage I Lung Cancer. The Annals Of Thoracic Surgery 2020, 110: 390-397. PMID: 32283084, DOI: 10.1016/j.athoracsur.2020.03.026.Peer-Reviewed Original ResearchConceptsStage I lung cancerI lung cancerMissed nodal metastasisClinical stage I lung cancerNodal metastasisLung cancerPositron emission tomographyStaging evaluationCancer patientsEndobronchial ultrasoundInvasive nodalClinical stage I patientsEarly-stage lung cancer patientsOccult lymph node metastasisEmission tomographyThoracic Surgeons General Thoracic Surgery DatabaseInvasive staging proceduresClinical stage IStage I patientsTreatment-naive patientsGeneral Thoracic Surgery DatabaseLow-risk cohortOccult nodal metastasisLymph node metastasisLung cancer patientsSurgically Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database
Sathe TS, Resio BJ, Hoag JR, Monsalve AF, Pathak R, Blasberg JD, Mase V, Dhanasopon A, Boffa DJ. Surgically Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database. The Annals Of Thoracic Surgery 2020, 109: 1656-1662. PMID: 32109449, DOI: 10.1016/j.athoracsur.2020.01.021.Peer-Reviewed Original ResearchConceptsSignet ring cell adenocarcinomaNational Cancer DatabaseSRC tumorsACA patientsCancer DatabaseProportional hazards regression modelsCommon histologic variantRole of esophagectomyClinical stage IRole of surgeryHazards regression modelsHigh-grade tumorsSRC histologySRC patientsAdult patientsComplete resectionWorse prognosisCell adenocarcinomaEsophageal cancerEsophageal carcinomaHistologic variantsSuperior survivalEsophageal adenocarcinomaTreatment characteristicsClinical recommendations
2019
Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV diseaseDifferential Safety Between Top-Ranked Cancer Hospitals and Their Affiliates for Complex Cancer Surgery
Hoag JR, Resio BJ, Monsalve AF, Chiu AS, Brown LB, Herrin J, Blasberg JD, Kim AW, Boffa DJ. Differential Safety Between Top-Ranked Cancer Hospitals and Their Affiliates for Complex Cancer Surgery. JAMA Network Open 2019, 2: e191912. PMID: 30977848, PMCID: PMC6481444, DOI: 10.1001/jamanetworkopen.2019.1912.Peer-Reviewed Original ResearchConceptsComplex cancer surgeryCancer surgeryCancer HospitalMedicare beneficiariesCancer NetworkRelative safetyStandardized mortality ratioComplex cancer careCross-sectional studyTop-ranked hospitalsMedicaid Services 100Hierarchical logistic regressionPerioperative mortalityAffiliated HospitalCancer careMortality ratioOdds ratioMAIN OUTCOMESurgeryHospitalReview filesDifferential safetyLogistic regressionMortalityMedicare providers
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatientsImproved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose
Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.Peer-Reviewed Original ResearchConceptsPopulation-based input functionStandardized uptake valueImage-derived input functionLung nodulesClinical trialsTime-activity curvesLow-dose computed tomography (LDCT) screeningLung cancer mortality ratesIndeterminate lung nodulesComputed Tomography ScreeningF-FDG PETCancer mortality ratesStatic PET acquisitionVirtual clinical trialsScan durationTomography screeningFDG injectionPET scansMortality rateUptake valueAccurate diagnosisMalignant lung nodulesROC analysisPatient dataMalignant nodulesDelayed discharge does not decrease the cost of readmission after pulmonary lobectomy
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD. Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy. Surgery 2018, 164: 1294-1299. PMID: 30064733, DOI: 10.1016/j.surg.2018.05.049.Peer-Reviewed Original ResearchConceptsRisk-adjusted readmission ratesReadmission ratesLate dischargeDischarge groupPulmonary lobectomyCostly readmissionsLung cancerHospital costsOverall health care utilizationExcess health care costsRoutine dischargeCosts of readmissionIndex hospital costsLate discharge groupRoutine discharge groupPatients 65 yearsNationwide Readmissions DatabaseHospital day 1Hospital day 4Health care utilizationCases of lobectomyHealth care costsIndex hospitalHospital durationCare utilizationWhen good operations go bad: The additive effect of comorbidity and postoperative complications on readmission after pulmonary lobectomy
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Blasberg JD, Kim AW. When good operations go bad: The additive effect of comorbidity and postoperative complications on readmission after pulmonary lobectomy. Surgery 2018, 164: 294-299. PMID: 29801731, DOI: 10.1016/j.surg.2018.03.019.Peer-Reviewed Original ResearchConceptsPostoperative complicationsReadmission ratesPulmonary lobectomyAdditional comorbiditiesThoracic surgeryCause readmission rateDays of dischargeNationwide Readmissions DatabaseNumber of comorbiditiesRisk of readmissionMajor thoracic surgeryProbability of readmissionLow risk profileHealth care deliveryHospital factorsHospital readmissionLow comorbidityElixhauser comorbiditiesThoracic lobectomyLung cancerPrimary diagnosisChronic diseasesHigh burdenMean changeValue-based reimbursementTiming and Risk Factors Associated With Venous Thromboembolism After Lung Cancer Resection
Thomas DC, Arnold BN, Hoag JR, Salazar MC, Detterbeck FC, Boffa DJ, Kim AW, Blasberg JD. Timing and Risk Factors Associated With Venous Thromboembolism After Lung Cancer Resection. The Annals Of Thoracic Surgery 2018, 105: 1469-1475. PMID: 29501644, DOI: 10.1016/j.athoracsur.2018.01.072.Peer-Reviewed Original ResearchConceptsPostdischarge venous thromboembolismVenous thromboembolismHospital dischargeOperative timeRisk factorsPostdischarge prophylaxisVTE eventsMultivariable analysisLung cancerNational Surgical Quality Improvement Program databaseQuality Improvement Program databaseExtended VTE prophylaxisLung cancer resectionImprovement Program databaseShorter operative timeLengthy resectionsVTE prophylaxisAnatomic resectionClinical characteristicsInvasive resectionLung resectionOlder patientsOpen resectionCancer resectionIndependent predictors
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvival
2016
Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer 2016, 103: 75-81. PMID: 28024700, DOI: 10.1016/j.lungcan.2016.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyDatabases, FactualFemaleGuidelines as TopicHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOutcome Assessment, Health CarePneumonectomyPostoperative PeriodRadiotherapySmall Cell Lung CarcinomaSurvival AnalysisConceptsStage I small cell lung cancerClinical stage ISmall cell lung cancerCell lung cancerAdjuvant chemotherapySurgical resectionPathologic upstagingStage IRadiation therapyNodal diseaseLung cancerPositive lymph node involvementNational Cancer DatabaseOutcomes of patientsLymph node involvementProportion of patientsCurative intentNodal upstagingSCLC patientsUpstaged patientsAdjuvant therapyNode involvementIndependent predictorsInferior survivalT descriptorLung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. Journal Of Thoracic Oncology 2016, 11: 1121-1131. PMID: 27103511, DOI: 10.1016/j.jtho.2016.03.023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseYounger patientsOlder patientsLung cancerRelative survivalStage IAdvanced stage non-small cell lung cancerCell lung cancerYears of ageAggressive therapyAggressive treatmentOverall survivalPatient demographicsPrimary outcomeTreatment patternsTumor characteristicsNSCLC casesPatientsStage IIIDetailed stagingSurvival informationOlder groupDistinct subsetsCancer
2015
The Surgical Apgar Score in esophagectomy
Janowak CF, Blasberg JD, Taylor L, Maloney JD, Macke RA. The Surgical Apgar Score in esophagectomy. Journal Of Thoracic And Cardiovascular Surgery 2015, 150: 806-812. PMID: 26234458, DOI: 10.1016/j.jtcvs.2015.07.017.Peer-Reviewed Original ResearchConceptsSurgical Apgar ScoreMajor morbidityApgar scorePostoperative complicationsMultivariate analysisPreoperative patient characteristicsShort-term outcomesBody mass indexStrongest predictorElective esophagectomyTranshiatal techniqueSurgical populationIntraoperative detailsIntraoperative variablesPatient characteristicsDiabetes mellitusPrimary outcomeRetrospective reviewMass indexProspective studyCare modificationsMalignant diseaseRisk factorsUnivariate analysisImproved outcomes
2012
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population
Joseph S, Harrington R, Walter D, Goldberg JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, Rom W, Pass H, Donington J. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomarkers 2012, 12: 177-184. PMID: 23568008, PMCID: PMC3746829, DOI: 10.3233/cbm-130306.Peer-Reviewed Original ResearchConceptsIncident cancerPlasma osteopontinNon-small cell lung cancer careLung cancer careCase-control studySerial plasmaNSCLC patientsCT screeningSurveillance intervalsCancer careLung cancerPlasma levelsWilcoxon Signed Rank TestDisease statusCancerSigned Rank TestBenign nodulesSecreted phosphoproteinCTRank testOsteopontinEarly evidenceNSCLCPatientsNSCLCs
2010
Robotic Brachytherapy and Sublobar Resection for T1 Non-Small Cell Lung Cancer in High-Risk Patients
Blasberg JD, Belsley SJ, Schwartz GS, Evans A, Wernick I, Ashton RC, Bhora FY, Connery CP. Robotic Brachytherapy and Sublobar Resection for T1 Non-Small Cell Lung Cancer in High-Risk Patients. The Annals Of Thoracic Surgery 2010, 89: 360-367. PMID: 20103299, DOI: 10.1016/j.athoracsur.2009.09.052.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overBrachytherapyCombined Modality TherapyComorbidityDisease ProgressionFemaleFollow-Up StudiesHealth Status IndicatorsHumansImage Processing, Computer-AssistedIodine RadioisotopesLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyPositron-Emission TomographyPostoperative ComplicationsRadiometryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRadiotherapy, AdjuvantRoboticsTomography, X-Ray ComputedConceptsNon-small cell lung cancerHigh-risk patientsCell lung cancerPlanning target volumeSublobar resectionLung cancerPrescription doseStage IA non-small cell lung cancerTarget volumeT1 non-small cell lung cancerSublobar lung resectionPatients 5 yearsSite of recurrenceIncidence of recurrenceComputed tomography scanBrachytherapy seed placementDa Vinci systemConventional lobectomyPerioperative mortalityLocoregional recurrenceLung resectionSelect patientsLimited resectionResection marginsTumor sizeReduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer
Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 936-941. PMID: 20085934, PMCID: PMC2834433, DOI: 10.1200/jco.2009.25.5711.Peer-Reviewed Original ResearchConceptsEarly-stage NSCLCPlasma osteopontin levelsPlasma OPN levelsOPN levelsEnzyme-linked immunosorbent assayPlasma OPNOsteopontin levelsWeeks postsurgeryElevated Plasma Osteopontin LevelsCell lung cancer correlatesUse of thoracotomyCell lung cancerLung cancer correlatesCancer-free smokersResectable NSCLCPerioperative eventsTumor characteristicsPresurgery levelsRecurrence rateValidation cohortLung cancerCancer correlatesTherapeutic responseNSCLCIndependent cohort